This is a prospective, open-label, multi-center, single-arm study enrolling subjects with severe heterogeneous emphysema and collateral ventilation in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe.

The purpose of this research study will be to evaluate the safety and effectiveness of two investigational drugs, All-trans retinoic acid (ATRA) and Retifanlimab (anti-PD1 monoclonal antibody), in treating recurrent IDH-mutant gliomas. Objective radiographic response (CR + PR + MR) using Response Assessment in Neuro-Oncology (RANO) criteria by measurable disease (assessed separately in Phase 2 Arms A and B). Rates and severity of adverse events per CTCAE (version 5.0) in the Safety Run-In and Phase 2 cohorts (Arms A and B). Rates and severity of adverse events per CTCAE (version 5.0) in the Surgical cohort (Arms C and D). Progression-free survival (PFS) in the Phase 2 Portion (Arms A and B): the time from date of enrollment until the earliest date of disease progression (as determined by modified RANO criteria) or death due to any cause, whichever occurs first. Progression-free survival (PFS) in the Surgical Portion (Arms C and D): the time from date of enrollment until the earliest date of disease progression (as determined by modified RANO criteria) or death due to any cause, whichever occurs first. Overall survival (OS) in the Phase 2 Portion (Arms A and B): the time from date of enrollment until death from any cause. Overall survival (OS) in the Surgical Portion (Arms C and D): the time from date of enrollment until death from any cause. Duration of response (CR or PR or MR) in Arms A and B: the time from date of initial scan of a response to date of the initial scan deemed tumor progression (as determined by modified RANO criteria).

The purpose of this study is to study a new radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body to see how it is taken up in the body and the brain using an imaging procedure called Positron Emission Tomography (PET/CT). Imaging PARP-1 activity in various cancers may help researchers to better understand it’s function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.